Zymeworks and Merck collaborate on "bispecific" antibodies

08/29/2011 | Xconomy

Canada's Zymeworks agreed to partner with Merck & Co. to develop "bispecific" antibody drugs for cancer and autoimmune conditions. The deal entitles Zymeworks to as much as $187 million in upfront and milestone fees, plus tiered royalties. Merck will gain exclusive global rights to market resulting therapies.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC